APA

Lynd L. D., Najafzadeh M., Colley L., Byrne M. F., Willan A. R., Sculpher M. J., Johnson F. R. & Hauber A. B. (20100920). Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Chicago

Lynd Larry D, Najafzadeh Mehdi, Colley Lindsey, Byrne Michael F, Willan Andrew R, Sculpher Mark J, Johnson F Reed and Hauber A Brett. 20100920. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Harvard

Lynd L. D., Najafzadeh M., Colley L., Byrne M. F., Willan A. R., Sculpher M. J., Johnson F. R. and Hauber A. B. (20100920). Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

MLA

Lynd Larry D, Najafzadeh Mehdi, Colley Lindsey, Byrne Michael F, Willan Andrew R, Sculpher Mark J, Johnson F Reed and Hauber A Brett. Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome. : Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 20100920.